NCT06415643招募中不适用
The Use of Islet Organoids in the Treatment of Pancreatic Surgery-related Diabetes
Zhejiang University1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2024年8月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- C-peptide secretion
研究概览
简要总结
The purpose of this clinical trial is to verify the safety and effectiveness of autologous islet organoids transplantation after in vitro expansion for the treatment of pancreatogenic diabetes.
详细描述
The purpose of this clinical trial is to verify the safety and effectiveness of autologous islet transplantation after in vitro expansion in the forms of functional islet organoids, for the treatment of pancreatogenic diabetes in participants who have undergone pancreatic resection through a single-center single-arm study. The investigators aim to establish the entire operational process of isolating expanding and transplanting islets from the pancreas removed from the participants and managing postoperative care. The investigators hope to accumulate clinical experience in treating pancreatogenic diabetes with transplanted autologous islet cell clusters expanded in vitro establish standard and regulated medical operations and gather materials for future applications of this treatment method in clinical practice.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily sign the informed consent form and adhere to the trial treatment plan and visit schedule.
- •When signing the informed consent form, the age should be between 18-70 years old, with no gender restrictions.
- •Good overall health condition: no damage to important organs such as heart, lungs, liver, kidneys, no serious or uncontrolled infections, and no history of severe mental disorders.
- •Meets the diagnosis of pancreatic tumor, chronic pancreatitis (diffuse pancreatic duct stones, refractory pain, associated with high risk of pancreatic cancer), pancreatic trauma, postoperative pancreatic fistula with class C, pancreatic cystic fibrosis, has indications for total or subtotal pancreatectomy, and no chronic organ failure.
- •Clinical examinations must meet the following criteria: Normal glycated hemoglobin (HbA1c) measurement.
- •Normal alanine aminotransferase (ALT) measurement, or abnormal but clinically insignificant
- •negative for Hepatitis A virus antibody (HAV antibody), Hepatitis B virus surface antigen (HBsAg) and e antigen, Hepatitis C virus antibody (HCV antibody), Human Immunodeficiency Virus antibody (HIV-1 and HIV-2 antibody), Syphilis antibody, Epstein-Barr virus antibody (EBV antibody), Cytomegalovirus (CMV-DNA), B19 virus nucleic acid, Human T-lymphotropic virus antibody.
- •Male participants who are sexually active and have not undergone surgical sterilization or whose partners are capable of childbearing, agree to take effective contraceptive measures for the entire trial period and at least 6 months after the end of the study, and not to donate sperm. Female participants capable of childbearing agree to take effective contraceptive measures for the entire study period and at least 6 months after the end of the study.
- •Post-pancreatic surgery blood sugar increase, meeting the diagnostic criteria for diabetes (World Health Organization 2019 edition).
- •C-peptide level <0.3 ng/mL 120 minutes after mixed meal stimulation before pancreatic islet transplantation.
排除标准
- •The investigator considers the following diseases to be clinically significant: a history of diabetes, or preoperative hyperglycemia, meeting the diagnosis of diabetes.
- •Undergone previous pancreatic or islet transplantation
- •Uncontrolled hypertension, such as systolic blood pressure (SBP) >160 mmHg and/or diastolic blood pressure (DBP) >100 mmHg after treatment with a stable dose (at least 4 weeks) of antihypertensive drugs.
- •Fatty hepatitis, portal vein thrombosis, portal hypertension, anterolateral pancreatic jejunostomy, or visceral hyperalgesia.Impaired liver and kidney function at screening (reference to the normal range of laboratory tests in the research center): aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN), alanine aminotransferase (ALT) >3 times ULN, total bilirubin level (TBL) >2 times ULN (excluding Gilbert's syndrome). Creatinine clearance <45 mL/min (calculated by Cockcroft-Gault formula)
- •Women in pregnancy, less than 6 months after miscarriage, less than 1 year after delivery and lactation.
- •History of infectious diseases including but not limited to hepatitis A, hepatitis B, hepatitis C, HIV and syphilis
- •Presence of known hemoglobin-related diseases, anemia (moderate to severe) or other known hemoglobin diseases that interfere with HbA1c measurement (such as sickle cell disease). Presence of massive albuminuria (urinary protein excretion rate >300 mg/g) or past medical history.
- •Presence of severe heart disease or cardiovascular disease within 6 months before screening, including: stroke, decompensated heart failure (NYHA class III or IV), myocardial infarction, unstable angina, those who have undergone coronary artery bypass grafting.
- •History of coagulation disorders or need for long-term anticoagulation treatment (such as warfarin) (low-dose aspirin treatment is allowed) or INR>1.5
- •Treatment (local, intra-articular, intraocular, or inhaled formulations) for any other factors or diseases, other than the above reasons, that the researcher deems unsuitable for participation in this clinical study.
结局指标
主要结局
C-peptide secretion
时间窗: before transplantation and 1 year after transplantation
C-peptide detection assay
次要结局
- Reduced Insulin usage(12 weeks and 52 weeks post transplantation)
- HbA1c level(before transplantation and 1 year after transplantation)
- Mean Amplitude of Glycemic Excursion (MAGE)(12 weeks and 52 weeks post transplantation)
- Ryan Hypoglycemia event(baseline and 52 weeks post transplantation)
研究者
Sheng Yan
Professor, MD
Zhejiang University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Islet Autotransplantation in Patients at Very High-risk Pancreatic AnastomosisPostpancreatectomy HyperglycemiaNCT01346098Ospedale San Raffaele60
进行中（未招募）
1 期
Allogenic Islet Cell TransplantationDiabetes Mellitus, Type 1NCT00160732University of Chicago50
已完成
1 期
Pancreatic Islet Transplantation Into the Gastric SubmucosaType 1 DiabetesNCT01571817Andrew Posselt1
进行中（未招募）
1 期
Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive RegimenDiabetes MellitusNCT00706420City of Hope Medical Center17
尚未招募
1 期
Clinical apprication of auto-islet transplantation for the patients recieved total pancreatectomy with non-malignant pancreatic tumorbenign pancreatic tumor, chronic pancreatitis, traumatic injury of the pancreasJPRN-UMIN000007119Tokushima univ10